PediCAP

is a 5-year research project focused on antibiotic therapy of severe and very severe childhood community acquired pneumonia

Through a collaboration between African and European partners it aims to provide data on optimal duration and oral step-down therapy for paediatric community acquired pneumonia.

Background

Community-acquired pneumonia is common and remains associated with substantial morbidity and mortality, especially in lower and middle-income countries. In Africa very severe pneumonia has a mortality of 10-15% among children. Childhood pneumonia is also a leading cause of hospitalization.

Antibiotics

Antibiotics are key to managing childhood pneumonia. WHO recommends injectable regimens, which cover a greater spectrum of bacterial pathogens but lead to longer hospital stays, high healthcare and societal costs, and to increased risks of nosocomial infections and acquisition of multidrug-resistant colonising bacteria. At present strong data to support a safe step-down to oral antibiotics, which would enable earlier discharge, are missing.

Capacity Building

PediCAP aims to establish an active community of practice between the research teams and collaborators which will firstly ensure the skills are in place to deliver a high-quality trial and associated sub-studies.  Secondly it will equip the participating sites in the South and the North with lasting capability to run, lead and design their own studies beyond this project.

Project Consortium / Partnership

Lead by Penta,  PediCAP project builds on long-standing collaboration between European experts in pediatric clinical trials and clinical partners in sub-Saharan Africa. The PediCAP consortium will build on this expertise, aiming to engage a younger generation of paediatricians and scientists who could become the future leaders in paediatric antibiotic clinical trials, providing the evidence for future national and global optimal prescribing guidelines.

PediCAP Roadmap

  • 2019

    Start date

    Start date

    April 1, 2019
  • 2020

    First ethical approval obtained

    First ethical approval obtained

    June 4, 2019
  • 2021

    First patient enrolled

    First patient enrolled

    January 1, 2020
  • 2022

    End of follow-up for all patients

    End of follow-up for all patients

    January 1, 2021
  • 2023

    First papers submitted to open access journal

    First papers submitted to open access journal

    January 1, 2022
  • 2024

    End date

    End date

    January 1, 2023